NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $14.62 +0.14 (+0.97%) Closing price 04:00 PM EasternExtended Trading$14.62 0.00 (-0.03%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Embecta Stock (NASDAQ:EMBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Embecta alerts:Sign Up Key Stats Today's Range$14.34▼$14.8250-Day Range$9.28▼$14.5952-Week Range$9.20▼$21.48Volume405,487 shsAverage Volume600,066 shsMarket Capitalization$855.05 millionP/E Ratio10.22Dividend Yield4.10%Price Target$19.00Consensus RatingModerate Buy Company Overview Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. Read More Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 93% of companies evaluated by MarketBeat, and ranked 70th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEmbecta has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageEmbecta has only been the subject of 2 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth7.72% Earnings GrowthEarnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 10.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 10.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.65.Price to Earnings Growth RatioEmbecta has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.47% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Embecta has recently decreased by 4.50%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 4.14%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 41.96%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.47% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Embecta has recently decreased by 4.50%, indicating that investor sentiment is improving. News and Social Media4.1 / 5News Sentiment1.32 News SentimentEmbecta has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.12 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Embecta this week, compared to 4 articles on an average week.Search Interest4 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Embecta to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.42% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMBC Stock News HeadlinesUpgrading Embecta Due To Reorganization And Growth InitiativesAugust 31 at 6:54 AM | seekingalpha.comEmbecta: Strategic Reprioritization Holds Promise And Valuations Are FavorableAugust 28, 2025 | seekingalpha.comTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.September 2 at 2:00 AM | Crypto 101 Media (Ad)embecta to Participate in Investor EventsAugust 26, 2025 | globenewswire.comEmbecta Corp. (NASDAQ:EMBC) Will Pay A US$0.15 Dividend In Four DaysAugust 24, 2025 | uk.finance.yahoo.comEmbecta's (NASDAQ:EMBC) Profits May Not Reveal Underlying IssuesAugust 16, 2025 | finance.yahoo.comEmbecta Corp. (NASDAQ:EMBC) Q3 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comWall Street Analysts Predict a 25.69% Upside in Embecta Corp. (EMBC): Here's What You Should KnowAugust 12, 2025 | msn.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $20.65 at the beginning of the year. Since then, EMBC shares have decreased by 29.2% and is now trading at $14.62. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) announced its earnings results on Friday, August, 8th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.35. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. Read the conference call transcript. Who are Embecta's major shareholders? Top institutional investors of Embecta include American Century Companies Inc. (8.89%), River Road Asset Management LLC (5.54%), Yacktman Asset Management LP (4.06%) and William Blair Investment Management LLC (3.41%). Insiders that own company stock include Devdatt Kurdikar, David F Melcher, Jacob Elguicze, Jeffrey Z Mann and Milton Mayo Morris. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Record date for 6/13 Dividend5/28/2025Ex-Dividend for 6/13 Dividend5/28/2025Dividend Payable6/13/2025Last Earnings8/08/2025Record date for 9/15 Dividend8/29/2025Ex-Dividend for 9/15 Dividend8/29/2025Today9/02/2025Dividend Payable9/15/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,100Year FoundedN/APrice Target and Rating Average Price Target for Embecta$19.00 High Price Target$25.00 Low Price Target$12.00 Potential Upside/Downside+30.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$1.43 Trailing P/E Ratio10.15 Forward P/E Ratio5.10 P/E Growth0.8Net Income$78.30 million Net Margins7.58% Pretax Margin9.10% Return on Equity-23.40% Return on Assets14.46% Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio1.78 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.76 Cash Flow$3.35 per share Price / Cash Flow4.34 Book Value($12.80) per share Price / Book-1.13Miscellaneous Outstanding Shares58,490,000Free Float58,239,000Market Cap$849.51 million OptionableOptionable Beta1.11 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EMBC) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.